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Several cell surface molecules, including HVEM and nectin-1, can serve as entry receptors for herpes simplex virus (HSV) and as
receptors for virus-induced or viral glycoprotein-induced cell fusion. The viral ligand for these receptors is the HSV envelope glycoprotein
gD. A set of linker-insertion and deletion mutants of HSV type 1 (HSV-1) gD was analyzed for effects of the mutations on binding of gD to
HVEM and nectin-1, on viral glycoprotein-induced cell fusion with target cells expressing HVEM or nectin-1 and on complementation of
infectivity of a gD-null HSV-1 viral mutant. Insertions after amino acid 151 or 225 or deletion of amino acids 234–244 disrupted (i) binding
of the mutant forms of gD to both receptors and (ii) functional interactions (cell fusion and complementation) with both receptors, but were
without effect on cell surface expression. Insertions in the N-terminal domain of gD (after amino acid 12, 34 or 43) disrupted binding to
HVEM and functional activities with HVEM, as expected from a previously reported X-ray structure of a gD–HVEM complex, but were
without effect in the case of nectin-1. These and other results indicate that the mutations disruptive of interactions with both receptors
probably affect conformations of contact sites that are different for each receptor.
D 2003 Elsevier Inc. All rights reserved.Keywords: Linker-insertion mutations; Herpes simplex virus 1 gD; Nectin-1Introduction
Five of the several glycoproteins in the herpes simplex
virus (HSV) envelope have been shown to participate in
HSV entry. Glycoproteins gC and/or gB mediate initial
attachment of the virus to the cell through interactions with
cell surface heparan sulfate (reviewed in Spear, 1993). Once
the virus is attached, gD can bind one of its multiple cell
surface entry receptors. Although the mechanisms are not
clear, gB, gD and the gH–gL heterodimer act together to
induce fusion of the viral envelope with a cell membrane,
but only upon interaction of gD with a gD receptor0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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7414.(reviewed in Spear et al., 2000). HSV also has the ability
to induce cell–cell fusion, which can result in the formation
of syncytia, or large multi-nucleated cells. This allows the
virus access to several nuclei in which it can replicate
without having to re-infect cells. The same glycoproteins
that have been shown to be required for HSV entry are also
necessary and sufficient for HSV-induced cell–cell fusion.
Cells expressing gB, gD and gH-gL can fuse with cells
expressing the appropriate gD receptor (Davis-Poynter et
al., 1994; Muggeridge, 2000; Pertel et al., 2001). Thus, the
viral and cellular determinants of HSV-induced cell–cell
fusion appear to be similar to those for viral entry.
Three classes of gD entry receptors have been described
to date: HVEM (herpesvirus entry mediator), the nectins and
3-O-sulfotransferase-modified heparan sulfate (reviewed in
Spear et al., 2000). HVEM, also known as HveA, ATAR or
TNFRSF14, is a member of the tumor necrosis factor
receptor family and has cysteine-rich pseudorepeats in its
ectodomain that are characteristic of the family (Montgom-
ery et al., 1996). Its natural ligands include LIGHT and
lymphotoxin-a (Mauri et al., 1998). Its HSV ligand, gD,
binds directly to residues in the N-terminal two pseudor-
C.R. Jogger et al. / Virology 318 (2004) 318–326 319epeats of HVEM (Carfi et al., 2001). HVEM is expressed on
a variety of cell types and can mediate the entry of both
HSV types 1 and 2 (HSV-1 and HSV-2); it is the principal
entry receptor used by HSV to infect certain cell types, such
as T lymphocytes, but appears not to be critical for entry
into a number of other cell types (Montgomery et al., 1996).
The nectins are members of the immunoglobulin (Ig)
superfamily and are related to the poliovirus receptor. They
have three Ig-like folds, V-like at the N terminus and C-like
in the membrane-proximal two domains. There are at least
four nectins (nectin-1, nectin-2, nectin-3, nectin-4), some of
which are widely expressed on many cell types and localize
to cadherin-based adherens junctions (reviewed in Takai and
Nakanishi, 2003). Only nectin-1 and nectin-2, also known
as HveC and HveB, respectively, have been shown to serve
as HSV entry receptors (Cocchi et al., 1998b; Geraghty et
al., 1998; Lopez et al., 2000; Warner et al., 1998). Nectin-1
can mediate the entry of HSV-1 and HSV-2, as well as the
animal alphaherpesviruses pseudorabies virus (PRV) and
bovine herpesvirus type 1. Nectin-2 mediates the entry of
HSV-2 and PRV, but has only very weak entry activity for
HSV-1. The N-terminal V-like domains of these molecules
have been shown to bind to gD (Cocchi et al., 1998a;
Geraghty et al., 2001; Krummenacher et al., 1998; Lopez et
al., 2000; Martinez and Spear, 2001). Several isoforms of
the heparan sulfate-modifying enzyme, 3-O-sulfotransfer-
ase, can generate sites in heparan sulfate for gD binding,
allowing for entry of HSV-1 preferentially (Shukla et al.,
1999; Xia et al., 2002).
HSV-1 gD is a type 1 membrane glycoprotein and has
369 amino acids after signal peptidase cleavage. It has three
sites for N-linked glycosylation and three disulfide bonds.
Crystal structures of a soluble truncated form of HSV-1 gD
(N-terminal 285 amino acids) were recently solved, with gD
alone or in complex with a soluble form of HVEM (Carfi et
al., 2001). It was determined that an Ig-like fold with an
unusual disulfide bonding pattern comprises the core of the
gD N-terminal domain. This core is flanked by an N-
terminal extension which contains the HVEM binding
region and forms a hairpin structure when bound to HVEM,
but is disordered in the crystals of gD alone. C-terminal of
the Ig-fold is an alpha helix that is sandwiched between the
N-terminal hairpin and the Ig-like core and appears to
support the HVEM contact site. Although the precise
binding sites for the other gD receptors have not yet been
defined, recent results show that at least a portion of the
contact region for nectin-1 must be downstream of amino
acid 32 and therefore downstream of the N-terminal hairpin
region (Yoon et al., 2003).
Mutations in gD that can reduce or enhance physical and
functional interactions with some of the HSVentry receptors
have been defined. Consistent with the X-ray structure of
gD-HVEM complexes, certain amino acid substitutions in
the HVEM contact regions (amino acids 7–15 and 24–32)
can prevent binding of HSV-1 gD to HVEM and also
prevent viral entry and cell fusion when HVEM is theentry/fusion receptor (Connolly et al., 2003; Montgomery
et al., 1996; Pertel et al., 2001; Whitbeck et al., 1997; Yoon
et al., 2003). Subsets of these substitutions in HSV-1 gD
actually enhance viral entry and cell fusion via nectin-2 and/
or inhibit viral entry and cell fusion via 3-O-sulfated
heparan sulfate (Connolly et al., 2003; Pertel et al., 2001;
Warner et al., 1998; Yoon et al., 2003). Another subset also
enhances entry/fusion activity with nectin-2 and somewhat
reduces, but does not eliminate, activity with HVEM (Con-
nolly et al., 2003; Lopez et al., 2000; Yoon et al., 2003).
However, these N-terminal substitutions in either HSV-1 or
HSV-2 gD have no effect on binding to nectin-1 or viral
entry and cell fusion via nectin-1 (Connolly et al., 2003;
Geraghty et al., 1998; Krummenacher et al., 1998; Yoon et
al., 2003). Finally, deletions encompassing one or both of
the HVEM contact regions (amino acids 7–15 and 24–32)
significantly reduce functional interactions (as assessed by
cell fusion) of either HSV-1 or HSV-2 gD with all the entry/
fusion receptors except nectin-1 (Yoon et al., 2003). Thus,
interactions of gD with the various entry/fusion receptors
are differentially affected by the mutations just described
and none of the mutations described has any demonstrable
effect on viral entry by, or cell fusion induced by, nectin-1.
A panel of gD linker-insertion mutants was previously
constructed to identify functional regions of gD important
for viral entry (Chiang et al., 1994). This study was
undertaken before the discovery of the HSV entry receptors
and made use of Vero cells, which express multiple primate
forms of the HSV entry receptors. Here we describe further
analysis of 21 of these mutants to determine which retain the
ability to bind soluble forms of HVEM or nectin-1, to
induce the fusion of cells expressing full-length HVEM or
nectin-1 and to mediate entry of virus into cells expressing
the full-length forms of HVEM and nectin-1. We have
identified a region of gD that is critical for binding and
functional interaction of gD with both HVEM and nectin-1.Results
Cell surface expression of gD mutants
All the gD mutants used in this study had previously
been shown to retain epitopes for at least two of seven
monoclonal antibodies (mAbs) and to be expressed on the
cell surface (Chiang et al., 1994), although cell surface
expression was not quantitatively assessed. To quantitate
cell surface expression under the conditions of the cell
fusion assay used here, CHO-K1 cells were co-transfected
with plasmids expressing HSV-1 gB, gH, gL and T7
polymerase, including also a plasmid expressing wild-type
HSV-1 gD or one of the HSV-1 gD mutants listed in Table
1. After seeding into 96-well plates, the transfected cells
were washed and incubated with an anti-gD rabbit serum
and then fixed and incubated sequentially with a biotin-
conjugated secondary antibody, streptavidin–horseradish
Table 1







pRE4 None none D1-HC235 ins 225 GRSS
D1-H28b ins 12c GKIFP pWW17d del 234–244 –
D1-N29 ins 34 GKIFL D1-H24 ins 243 GRSS
D1-H27 ins 43 EDLP D1-H54 ins 246a GKIFP
D1-H78 ins 77a GKIFP D1-N1 ins 246b EDLP
D1-N65 ins 83 GRSS D1-H26 ins 277 GKIFP
D1-H104 ins 84 GKIFP D1-N2 ins 287 EDLP
D1-N22 ins 125 GRSS D1-H15 ins 310 GKIFRKIFP
D1-H98 ins 126 GKIFP pHC238 del 277–290 GKIFP
D1-N37 ins 151 WKIFL pHC240 del 290–300 GKIFP
D1-N119 ins 187 GRSS pHC241 del 290–310 GKIFP
a Described by Chiang et al. (1994).
b D1 refers to the gD gene of HSV-1. The letter after the dash refers to the
restriction enzyme used (H, HaeIII; N, NlaIV).
c ins, insertion-number indicates the amino acid residue preceding the
insertion; del, deletion of the residues indicated.
d Constructed as described by Cohen et al. (1988).
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show that all the gD mutants were expressed on the surfaces
of CHO cells at or near wild-type levels, with the exception
of ins246b and ins277.
Binding of soluble receptors to gD mutants
We used soluble secreted forms of entry/fusion recep-
tors, hybrids of the HVEM and nectin-1 ectodomains fusedFig. 1. Cell surface expression of HSV-1 gD mutants. CHO-K1 cells were
co-transfected with plasmids expressing HSV-1 gB, gH, gL and T7
polymerase, including also a plasmid expressing one of the HSV-1 gD
mutants, wild-type gD or an empty control vector. After seeding into 96-
well plates, the transfected cells were incubated with an anti-gD rabbit
serum, then washed and fixed and incubated with an HRP-based detection
system. Percent of wild-type gD = {(HRP units for mutant gD  HRP units
for control)/(HRP units for wild-type gD  HRP units for control)}  100.
The results presented here are the means of three independent experiments
(each done in triplicate) with standard deviation.to the Fc region of rabbit IgG (HVEM:Fc and nectin-1:Fc),
to test whether the mutant forms of gD retained receptor-
binding activity. For these studies, CHO-K1 cells were co-
transfected with plasmids expressing gB, gH, gL and T7
polymerase, including also a plasmid expressing one of the
gD mutants or wild-type gD. After seeding in 96-well
plates, the transfected cells were washed and incubated
with HVEM:Fc or nectin-1:Fc at 10 ng/ml, and then fixed
before incubation with a detection system specific for the
Fc domain. The results of these binding studies are shown
in Figs. 2 and 3. The gD mutants fell into three categories,
according to their ability to bind HVEM:Fc and nectin-
1:Fc. Mutants in the first category (ins77, ins83, ins84,
ins187, ins277, ins287, ins310, del277–290, del290–300,
del290–310) retained the ability to bind both receptors at
levels greater than 50% than that observed for wild-type
gD. Mutants in the second category (ins12, ins34, ins43,
ins125, ins126, ins243, ins246a) were impaired for binding
to HVEM:Fc, but not to nectin-1:Fc. Mutants in the third
category (ins151, ins225, del234–244, ins246b) wereFig. 2. Binding and fusion activities of gD mutants with HVEM. Each
mutant was tested for binding (black bars) and fusion (gray bars) activity in
comparison with wild-type gD. CHO-K1 cells were co-transfected with
plasmids expressing HSV-1 gB, gH, gL and T7 polymerase, including also
a plasmid expressing one of the HSV-1 gD mutants, wild-type gD or an
empty control vector. To determine binding activity, the transfected cells
were seeded in 96-well plates, incubated with HVEM:Fc (10 ng/ml),
washed, fixed and incubated with an HRP-based detection system. Percent
of wild-type gD = {(HRP units for mutant gD  HRP units for control)/
(HRP units for wild-type gD  HRP units for control)}  100. HRP unit
values (OD370) for wild-type gD ranged from 0.332 to 0.353 and for the
negative control from 0.125 to 0.138. To measure fusion activity, cells
expressing wild-type or a mutant form of gD, along with gB, gH-gL and T7
polymerase, were mixed with CHO-HVEM cells transfected with a T7
luciferase plasmid. Luciferase activity was quantitated as a measure of
fusion. Percent of wild-type gD = {(luciferase activity for mutant gD 
luciferase activity for control)/(luciferase activity for wild-type gD 
luciferase activity for control)}  100. Values (luciferase activity in
arbitrary units) for wild-type gD ranged from 4743 to 10,097 and for the
negative control from 57 to 142. Means and standard deviations for
triplicate determinations in a single experiment are shown. Similar results
were obtained in two other experiments.
Fig. 3. Binding and fusion activities of gD mutants with nectin-1. Each
mutant was tested for binding (black bars) and fusion (gray bars) activity in
comparison with wild-type gD. Methods and data analysis are as described
in the legend to Fig. 2 except that nectin-1:Fc was used for the binding
assay and CHO-nectin-1 cells as the targets in the cell fusion assay. For the
binding assay, HRP unit values (OD370) for wild-type gD ranged from
1.007 to 1.105 and for the negative control from 0.293 to 0.332. For the cell
fusion assay, values (luciferase activity in arbitrary units) for wild-type gD
ranged from 56,659 to 60,395 and for the negative control from 666 to
2093. Means and standard deviations for triplicate determinations in a
single experiment are shown. Similar results were obtained in two other
experiments.
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obtained with mutant ins246b might be explained in part
by its reduced or altered presentation on cell surfaces (Fig.
1). None of the mutants was impaired for binding to
nectin-1 while also retaining significant binding activity
for HVEM.
Functional analysis of the gD mutants
The effects of the mutations on gD function were
assessed first in a virus-free, quantitative cell fusion assay.
This assay depends on the expression of four HSV-1
glycoproteins (gB, gD, gH and gL) and T7 polymerase in
one cell population (effector cells) and on expression of an
entry/fusion receptor, and presence of a luciferase gene
driven by the T7 promoter, in a second cell population
(target cells). The effector cells were co-transfected with
plasmids expressing HSV-1 gB, gH, gL and T7 polymerase,
including also a plasmid expressing one of the gD mutants
or wild-type gD, and then mixed with target cells expressing
HVEM or nectin-1. The extent of fusion was assessed by
quantitating luciferase expression. The results obtained are
presented in Figs. 2 and 3 along with the receptor-binding
results just described. In general, cell fusion activity corre-
lated with receptor-binding activity. In some cases, greater
cell fusion activity (normalized to control values obtained
with wild-type gD) was retained than might have been
predicted on the basis of the receptor-binding results. Thismay be explained in part by potential differences between
soluble and membrane-bound forms of receptor in ability to
interact with mutant forms of gD. Fig. 2 shows that
mutations in the N-terminal region of gD (ins12, ins34
and ins43) severely reduced the fusion of effector cells with
the HVEM-expressing target cells (<50% the level observed
with wild-type gD), as did mutations in other domains of gD
(ins151, ins225, del234–244, ins243 and ins246b). These
same mutations severely disrupted binding with HVEM:Fc.
On the other hand, only three mutations (ins151, ins225
and del234–244) disrupted both the binding of nectin-1:Fc
and the fusion of effector cells with nectin-1-expressing
target cells. Mutation ins151 had a less drastic effect on
fusion with nectin-1-expressing target cells than with
HVEM-expressing target cells, whereas mutations ins225
and del234–244 drastically reduced fusion with both target
cells. In a recent study, many of the same gD mutants used
here were expressed in baby hamster kidney (BHK) cells,
along with HSV-1 gB, gH and gL, to assess cell fusion
activity. Binding of a soluble nectin-1:Fc hybrid to BHK
cells expressing the various gD mutants was also quantitat-
ed. The results obtained were different from those presented
in Fig. 3, most notably in findings of reduced cell fusion and
nectin-1-binding activities for the N-terminal insertion
mutants, ins12, ins34, ins43 (Zhou et al., 2003). Because
the levels of gD cell surface expression were not assessed in
the cited study, the differences noted could be trivial and
relate only to efficiencies of transfection and expression
from the various plasmids. The differences in cell fusion
results could also be explained by expression of human
nectin-1 in the target cells used here (Fig. 3) and BHK entry/
fusion receptors, which have not yet been fully identified or
characterized, in the target cells used in the cited study. The
differences in nectin-1:Fc binding results could be due to
various factors, including use of different hybrid forms of
nectin-1 at different concentrations (nectin-1:Fc-rabbit at 10
ng/ml in this study versus nectin-1:Fc-human at 600 ng/ml
in the cited study) or expression of the gD mutants in
different cell types. BHK cells express functional HSV
entry receptors, whereas CHO cells have only very weak
endogenous receptors for HSV-1. Through an interference
phenomenon (Geraghty et al., 2000), the endogenous recep-
tors in BHK cells could compete with soluble nectin-1 for
binding to some of the gD mutants.
To address whether the mutant forms of gD were
functional for viral entry via HVEM or nectin-1, we used
the complementation assay previously described (Chiang et
al., 1994) but with several modifications. Vero cells were
transfected with a plasmid expressing wild-type gD or one
of the mutant forms of gD and then treated with cyclohex-
imide (50 Ag/ml) to delay the synthesis of gD until after the
cells had been infected with a complemented gD-null virus,
to prevent gD-mediated interference (Geraghty et al., 2000).
At 24 h after transfection, the cells were washed free of
cycloheximide and infected with the gD-null virus, HSV-
1(KOS)gD6. Complemented virus particles were then har-
Fig. 5. Ability of gD mutants to mediate viral entry into CHO-nectin-1
cells. Each gD mutant was tested for ability to complement the entry defect
of a gD-null HSV-1 viral mutant (gray bars) in comparison with wild-type
gD. Results are presented along with the cell fusion results from Fig. 3
(black bars), for comparison. Methods and data analysis are as described in
the legend to Fig. 4 except that the complemented viruses were tested for
entry into CHO-nectin-1 cells. Values (OD410 of ONPG reaction product)
for wild-type gD ranged from 0.151 to 0.153 and for the negative control
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cells. The results are presented in Figs. 4 and 5, in
comparison with the cell fusion results from Figs. 2 and 3.
In general, the complementation results paralleled the cell
fusion results. Mutations that impaired cell fusion activity
the most also significantly reduced complementation of viral
infectivity, in a receptor-dependent fashion. With some
exceptions, the complementation results obtained here also
paralleled the complementation results obtained previously
with Vero cells (Table 2). Most of the exceptions were
results obtained with the N-terminal mutations (ins12, ins34,
ins43). On the basis of their complementation activities, the
gD mutants fall into four categories: (1) similar comple-
mentation activities with all three cell types; (2) similar only
with CHO-HVEM cells and Vero cells; (3) similar only with
CHO-nectin-1 cells and Vero cells; and (4) similar only with
CHO-HVEM and CHO-nectin-1 cells. Vero cells express
the monkey forms of both HVEM and nectin-1 (Foster et al.,
1999; Milne et al., 2001), and possibly other entry receptors,
but features of HSV-1 gD that govern interactions with
monkey entry receptors are not known.
Retention of cell fusion activity by some of the gD
mutants analyzed here did not necessarily predict compara-
ble complementation of viral infectivity (Figs. 4 and 5).Fig. 4. Ability of gD mutants to mediate viral entry into CHO-HVEM cells.
Each gD mutant was tested for ability to complement the entry defect of a
gD-null HSV-1 viral mutant (gray bars) in comparison with wild-type gD.
Results are presented along with the cell fusion results from Fig. 2 (black
bars), for comparison. Vero cells were transfected with a plasmid expressing
wild-type gD or one of the mutant forms of gD and treated with
cycloheximide (50 Ag/ml). After 24 h, the cells were washed and infected
with 20 PFU/cell of HSV-1(KOS)gD6. After an additional 24 h,
complemented virus particles were harvested and used to inoculate CHO-
HVEM cells. After 6 h, the cells were lysed for the quantitation of h-
galactosidase activity (OD410 of ONPG reaction product) as a measure of
viral entry. Percent of wild-type gD = {(ONPG units for mutant gD 
ONPG units for control)/(ONPG units for wild-type gD  ONPG units for
control)}  100. Values for wild-type gD ranged from 0.145 to 0.150 and
for the negative control from 0.099 to 0.106. Results presented are the
means of triplicate determinations.
from 0.101 to 0.103. Results presented are the means of triplicate
determinations.Most of the insertions upstream of residue 151 impaired
complementation of viral infectivity more than cell fusion
activity. Also, del277–290, del290–300 and, in particular,
del290–310 reduced complementation but not cell fusionTable 2
Complementation assays of linker-insertion mutants






ins 12 5 47 96
ins 34 3 35 2
ins 43 17 80 9
ins 77a 0 21 16
ins 83 35 40 77
ins 84 36 53 115
ins 125 15 40 21
ins 126 4 34 17
ins 151 0 10 0
ins 187 98 83 79
ins 225 7 6 0
del 234–244 0 11 nd
ins 243 12 33 3
ins 246a 19 25 1
ins 246b 4 12 1
ins 277 58 56 44
ins 287 131 91 59
ins 310 121 91 105
del 277–290 47 46 12
del 290–300 40 24 7
del 290–310 2 4 14
a Data from Chiang et al. (1994).
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deletion mutants when tested on Vero cells (Table 2).
Reduced complementation could have resulted from im-
paired incorporation of the mutant forms of gD into virions
or reduced entry activity of the incorporated gD or both. The
experiments done to date cannot differentiate among these
possibilities. This will require transfer of interesting muta-
tions to the viral genome so that purified progeny produced
in the absence of complementation can be analyzed as to
composition and specific infectivity.Fig. 6. Structure of HSV-1 gD and location of insertions/deletions that
disrupted functional interactions with HVEM alone (dark green) or with
both HVEM and nectin-1 (black). This ribbon backbone trace is based on
coordinates deposited in the Protein Data Bank (1JMA) for the structure of
gD in complex with HVEM (Carfi et al., 2001). HVEM is not shown here.
The HVEM contact regions (7–15 and 24–32) are colored light green. N =
N terminus; C = C terminus.Discussion
Results presented here identify regions of HSV-1 gD
that are critical for functional interactions with the two
major HSV-1 entry receptors, HVEM and nectin-1, and
also provide additional evidence that the N-terminal do-
main of gD is critical for interactions with HVEM, but not
with nectin-1. The mutations ins151, ins225 and del234–
244 disrupted binding of soluble HVEM:Fc and nectin-
1:Fc to cells expressing the gD mutants and also disrupted
cell fusion activity and complementation activity of the
mutants whether the fusion/entry receptors were HVEM or
nectin-1. As previously shown (Chiang et al., 1994;
Muggeridge et al., 1990), ins151, ins225 and del234–
244 also disrupted complementation activity when the
fusion/entry receptors were those expressed in Vero cells.
These results are not due to absence of gD cell surface
expression or loss of epitopes recognized by a polyclonal
antiserum, as shown in Fig. 1. Also, ins225 and del234–
244 retained epitopes for 5/7 and 6/7 mAbs tested,
respectively (Chiang et al., 1994; Muggeridge et al.,
1990). Ins151, on the other hand, retained epitopes for
only 2/7 mAbs, indicating significant changes in confor-
mation (Chiang et al., 1994).
Consideration of our results and the X-ray structure of
gD (Carfi et al., 2001) indicates that the mutations most
disruptive of binding to both HVEM and nectin-1, and of
functional activity with HVEM and nectin-1, are predicted
to disrupt critical secondary structural elements of gD (Fig.
6). Ins151 would bisect the E beta strand of the Ig fold.
Ins225 would interrupt the N-terminal end of alpha helix 3,
which is sandwiched between the N-terminal domain and
the Ig fold. Del234–244 removes the C-terminal half of
alpha helix 3. It seems likely that these mutations alter the
conformation of gD so as to preclude binding of both
HVEM and nectin-1, without affecting the folding and
processing necessary for transport to the cell surface. Only
two other mutations studied here are predicted to disrupt
similar structural elements. Ins77 and ins83 should affect
alpha helix 1, a small helix within a large surface loop.
These latter insertions had little effect on binding or cell
fusion with nectin-1 as receptor, and caused only marginal
impairment of these activities with HVEM. Ins77 did,
however, impair complementation of viral entry via bothreceptors. All the other insertions or deletions analyzed here
were in regions of loops or were downstream of the portion
of gD that was ordered in the X-ray structure (downstream
of amino acid 259). Because the mutants studied here
passed the tests of epitope retention and transport to the
cell surface, it is perhaps not surprising that few of the
insertions or deletions were in structural elements such as
beta strands and alpha helices.
Our results are consistent with previous studies that
mapped epitopes of gD critical for interactions with HVEM
and nectin-1. mAbs specific for several distinct or over-
lapping antigenic sites were tested for ability to block the
binding of HVEM or nectin-1 to HSV-1 virions. Only mAbs
1D3 (site VII) and DL11 (site Ib) inhibited the binding of
HVEM to virions (Nicola et al., 1998). The linear epitope
recognized by 1D3 has been mapped to amino acids 11–19
and the conformational epitope recognized by DL11 to
regions upstream of amino acid 258 (Cohen et al., 1992).
Only mAbs HD1 (site Ia) and DL11 (site Ib) inhibited the
binding of nectin-1 to virions (Krummenacher et al., 1998).
Sites Ia and Ib are overlapping conformational epitopes with
site Ia mapping to a region upstream of amino acid 226
(Cohen et al., 1992). It is of interest that mutation ins12
reduced the binding of mAb 1D3 only partially, whereas all
the other mutations tested here, including those that
inhibited interaction with HVEM, had no effect on 1D3
binding (Chiang et al., 1994). Mutations ins151, ins225 and
del234–244, all of which inhibited functional interactions
with both HVEM and nectin-1, abrogated the binding of
mAb DL11, but only ins151 prevented binding of mAb
HD1 (Chiang et al., 1994; Muggeridge et al., 1990). Ins151
also inhibited the binding of three other mAbs specific for
C.R. Jogger et al. / Virology 318 (2004) 318–326324other conformational antigenic sites (Chiang et al., 1994),
indicating that this mutation altered the overall conforma-
tion of gD despite its lack of effect on cell surface expres-
sion and only partial inhibition of cell fusion activity with
nectin-1.
The results presented here have not only identified
regions of gD that are critical for integrity of the contact
regions for both HVEM and nectin-1, but also provide
additional evidence that the primary contact regions are
largely non-overlapping. Insertions in the N terminus of gD
(ins12, ins34, ins43) disrupted physical and functional
interactions with HVEM, as predicted from the X-ray
structure of the HVEM–gD complex, but were without
effect on binding of gD to nectin-1, cell fusion with
nectin-1 as receptor and complementation of viral entry
via nectin-1. This is consistent with previous findings that
amino acid substitutions in the N-terminal domain of gD,
and deletions encompassing amino acids 7–32 of gD,
disrupt interactions with HVEM, but not nectin-1 (Connolly
et al., 2003; Geraghty et al., 1998; Krummenacher et al.,
1998; Montgomery et al., 1996; Whitbeck et al., 1997; Yoon
et al., 2003). Thus, while the principal gD–HVEM interface
is between amino acids 7 and 32, the principal gD–nectin-1
interface must be downstream of amino acid 32. The
possibility exists that there may be secondary overlapping
interfaces with HVEM and nectin-1, one interpretation of
the findings described above that mAb DL11 can block the
binding of both HVEM and nectin-1 to virions. Other
interpretations of the effects of DL11 are that (i) binding
of DL11 to its epitope sterically hinders interaction with
both receptors even though their contact interfaces are
different or (ii) binding of DL11 causes conformational
changes that alter distinct and different interfaces for each
of the receptors. If there are no overlaps in the contact
interfaces for HVEM and nectin-1, then the mutations
described above that disrupt interactions with both HVEM
and nectin-1 must alter conformation of both of the non-
overlapping primary interfaces, including the N-terminal
hairpin structure important for binding to HVEM.
It is of interest that none of the mutations analyzed here
disrupted cell fusion activity or complementation of viral
entry without also disrupting binding to receptor. If the
binding of gD to receptor leads to interaction of gD with
one of the other HSV glycoproteins known to be required
for membrane fusion (gB, gH or gL), it might be expected
that there is an interface on gD for one of the other viral
glycoproteins. Disruption of this interface would be pre-
dicted to inhibit cell fusion without necessarily affecting
binding of gD to receptor. This possibility is not ruled out
by our results because the gD open reading frame was not
saturated with mutations that were suitable for analysis and
because deletions or insertions might cause changes too
drastic to permit identification of a domain that is critical
only to events occurring after binding of gD to receptor.
Point mutations, generated with guidance from the X-ray
structure, may permit identification of regions in gD thatare critical for cell fusion activity but not for receptor
binding.Materials and methods
Cells and viruses
CHO-K1 cells were provided by J. Esko (University of
California at San Diego). CHO-K1 cells stably expressing
HVEM, designated CHO-HVEM35 cells, were obtained by
transfection with plasmid pBEC28 (see below) and selec-
tion in medium containing G418 at 500 Ag/ml (R.I.
Montgomery and P.-Y. Lim, manuscript in preparation).
Nectin-1-expressing CHO cells were previously described
(Geraghty et al., 1998; Montgomery et al., 1996). All CHO
cell lines were passaged in Ham’s F12 medium (Gibco
BRL) supplemented with 10% fetal bovine serum (FBS)
and antibiotics, including G418 (400 Ag/ml) for stably
transfected cells. HSV-1(KOS)gD6 is a gD-negative virus
in which the gD open reading frame has been replaced by
the lacZ gene under control of the CMV IE promoter
(Warner et al., 1998). Stocks of this gD-negative mutant
were propagated on the complementing VD60 cells (Ligas
and Johnson, 1988).
Plasmids
Plasmids expressing HSV-1(Patton) gD linker-insertion
and deletion mutants, which were generously provided by
G. Cohen and R. Eisenberg (University of Pennsylvania,
Philadelphia), were previously described (Chiang et al.,
1994; Cohen et al., 1988) and are listed in Table 1. For
construction of plasmid pBEC28, the open reading frame
for HVEM was amplified by polymerase chain reaction
(PCR) from pBEC10 (Montgomery et al., 1996) using a 3V
primer in which the stop codon was replaced with
GAATTCGC. The resulting PCR product was digested with
NheI and EcoRI and then cloned into the same sites present
in the pcDNA3.1mycHIS B vector (Invitrogen, Inc.). Plas-
mid pBL58, expressing the human HVEM ectodomain
fused to the hinge, CH2 and CH3 domain of the rabbit
IgG heavy chain (HVEM:Fc) was previously described
(Montgomery et al., 1996). Plasmid pBL60 has the
HVEM:Fc hybrid open reading frame from pBL58 cloned
into a derivative of pPUR (Clontech), in which the cyto-
megalovirus promoter for the puromycin-resistance gene
was replaced with the Rous sarcoma virus promoter. Plas-
mid pBG37 expresses the equivalent human nectin-1:rabbit
IgG fusion protein (nectin-1:Fc). It was constructed by PCR
amplification of the nectin-1 ectodomain (nucleotides
encoding the first 336 amino acids including the cleavable
signal sequence) and ligation to the Fc region of rabbit IgG
by a BamHI site such that amino acid F336 of nectin-1 is
fused to a linker encoding two amino acids (GS) and then to
amino acid A175 of rabbit IgG (GenBank accession number
C.R. Jogger et al. / Virology 318 (2004) 318–326 325K00752.1). The hybrid open reading frame was inserted into
pcDNA3 (N.A. Jones and R.J. Geraghty, manuscript in
preparation).
Preparation of HVEM:Fc and nectin-1:Fc
A stable cell line that secretes HVEM:Fc was produced
by transfection of CHO-K1 cells with pBL60 and selection
in medium containing puromycin (5 Ag/ml). The cells were
plated in complete medium (Ham’s F12 plus 10% FBS) and,
24 h later, were washed and transferred to Opti-MEM
(Gibco BRL). Culture supernatants containing the secreted
HVEM:Fc were collected 48 h later. To produce the nectin-
1:Fc protein, PEAK cells (Edge Biosystems) were trans-
fected with the plasmid pBG37 by the calcium phosphate
method in DMEM containing 5% FBS. Twenty-four hours
after transfection, the cells were washed and incubated with
Opti-MEM and culture supernatants were collected 48
h later. The culture supernatants containing the secreted
proteins were clarified by low-speed centrifugation and the
concentration of the receptor:Fc hybrid proteins was deter-
mined by enzyme-linked immunosorbent assay (ELISA)
with reagents that detected the rabbit Fc region.
Cell enzyme-linked immunosorbent assay (CELISA)
Subconfluent CHO-K1 cells were transfected with plas-
mids expressing the HSV-1 fusion-inducing glycoproteins
and T7 RNA polymerase using Lipofectamine reagent in
Opti-MEM. Individual wells of six-well plates were trans-
fected with 0.5 Ag of each plasmid, keeping the total amount
of DNA at 2.5 Ag per well by the addition of empty vector
DNA, if necessary. After incubation at 37jC in 5% CO2 for
8 h, the transfection mixture was removed and Ham’s F12
medium containing 10% FBS was added. The cells were
incubated for an additional 4 h before detaching and replat-
ing into 96-well plates. After incubation for 18 h, the cells
were washed with phosphate-buffered saline (PBS) and then
incubated with primary antibody, HVEM:Fc or nectin-1:Fc
diluted in PBS containing 3% bovine serum albumin. Rabbit
polyclonal anti-gD antibody, R7, was diluted 1:10,000;
HVEM:Fc and nectin-1:Fc supernatants were used at 10
ng of receptor:Fc hybrid per milliliter. Subsequently, the
cells were washed, fixed with PBS containing 2% formal-
dehyde and 0.2% glutaraldehyde, and incubated sequential-
ly with biotinylated anti-rabbit IgG (Sigma), Amdex
streptavidin-conjugated horseradish peroxidase (HRP;
Amersham) and HRP substrate (BioFx Lab). Binding was
monitored at 370 nm in a Victor Wallac spectrophotometer
(Perkin-Elmer).
Cell fusion assay
The assay conditions and plasmids used were as previ-
ously described (Pertel et al., 2001), except that the gD-
expressing plasmid used previously was replaced with oneof the gD-expressing plasmids listed in Table 1. CHO-K1
effector cells were transfected with the plasmids expressing
the HSV-1 fusion glycoproteins (gB, gD, gH and gL) and
T7 RNA polymerase. Target CHO-HVEM or CHO-nectin-1
cells were transfected with the plasmid expressing luciferase
under control of the T7 promoter. After incubation at 37jC
in 5% CO2 for 8 h, the transfection mixture was removed
and Ham’s F12 medium containing 10% FBS was added.
The cells were incubated for an additional 4 h before
detaching and replating into 96-well plates. Effector and
target cells were mixed in a 1:1 ratio, and co-cultivated for
18 h. Luciferase activity was quantitated using the Lucifer-
ase Reporter Assay System (Promega).
Complementation assay
The procedure was performed as previously described
(Chiang et al., 1994) with several modifications. Vero cells
were transfected using Lipofectamine in Opti-MEM (Gibco
BRL) with gD expression plasmids or an empty vector.
After 6 h, the transfection mixture was removed and DMEM
containing 10% FBS and cycloheximide (50 Ag/ml) was
added. Then, 24 h after transfection, the cells were washed
with DMEM containing 10% FBS and incubated with 20
PFU/cell of complemented HSV-1(KOS)gD6 virus for 2 h at
37jC. The medium was removed and the extracellular virus
was inactivated by the addition of citrate buffer (pH 3.0) for
1 min followed by two washes with PBS supplemented with
1% glucose and 1% calf serum. The cells were overlaid with
fresh DMEM containing 1% serum and incubated for 24 h at
37jC. The infected cells were harvested by scraping into the
culture supernatant. The cells were disrupted by sonication,
and debris removed by low-speed centrifugation. Samples
of the complemented viruses were added in triplicate to
CHO-HVEM and CHO-nectin-1 cells grown in 96-well
plates and incubated for 6 h. Cells were washed, permeabi-
lized and incubated with h-galactosidase substrate, O-nitro-
phenyl-h-D-galactopyranoside (ONPG; Sigma) as described
(Montgomery et al., 1996). The reaction was monitored at
405 nm to quantitate viral entry.Acknowledgments
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